The results of this study confirm our hypothesis that the PSMA-targeted Auger emitter 125I-DCIBzL demonstrates a higher therapeutic ratio than the analogous α-particle emitter 211At-PSMA-6 in an in vivo murine model of micrometastatic PC 16,18. This evidence concerns the gene FOLH1 and pachyonychia congenita.